Advertisement
Advertisement
ALNY
Alnylam Pharmaceuticals, Inc.
317.46
USDSponsored
-10.70
-3.26%
Mar 27, 16:00 UTC -4
Closed
After-Market
318.07
+0.61
+0.19%
ALNY Earnings Reports
Positive Surprise Ratio
ALNY beat 21 of 40 last estimates.
53%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.15B
/$1.00
Implied change from Q4 25 (Revenue/ EPS)
+4.70%
/+21.95%
Implied change from Q1 25 (Revenue/ EPS)
+93.30%
/-327.27%
Alnylam Pharmaceuticals, Inc. earnings per share and revenue
On Feb 12, 2026, ALNY reported earnings of 0.82 USD per share (EPS) for Q4 25, missing the estimate of 1.14 USD, resulting in a -28.48% surprise. Revenue reached 1.10 billion, compared to an expected 1.20 billion, with a -8.29% difference. The market reacted with a -4.28% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 16 analysts forecast an EPS of 1.00 USD, with revenue projected to reach 1.15 billion USD, implying an increase of 21.95% EPS, and increase of 4.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-Actual
-$0.71
Surprise
-
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
What were Alnylam Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Alnylam Pharmaceuticals, Inc. reported EPS of $0.82, missing estimates by -28.48%, and revenue of $1.10B, -8.29% below expectations.
How did the market react to Alnylam Pharmaceuticals, Inc.'s Q4 2025 earnings?
The stock price moved down -4.28%, changed from $322.28 before the earnings release to $308.48 the day after.
When is Alnylam Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Alnylam Pharmaceuticals, Inc.'s next earnings report?
Based on 16
analysts, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.00 and revenue of $1.15B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement